Jan. 15 at 6:01 PM
$ABSI They haven't proven their AI abilities yet. 101 failed and 201 was brought to them from their own researcher's prior work. So far they look like a start-up drug developer with vapor AI label. NPV seems to be based soley on success/failure of 201 because it is a binary factor for their survival. MS assigns 25% probability to success of 201, which means if/as Absci does anything to increase the perception of the probability of success, like a successful phase 1 trial, then event becomes instant multiplier (probably 3x) for stock price. If Absci does something to show successful de novo development by AI (301?), then they can get a valuation similar to Recursion.
